32.45

3.48% -1.17

Indivior Pharmaceuticals Inc (INDV)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Indivior Pharmaceuticals Inc stock is traded at $32.45, with a volume of 4.21M. It is down -3.48% in the last 24 hours and down -5.53% over the past month. Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Previous Close:

$33.62

Open:

$33.47

24h Volume:

4.21M

Relative Volume:

1.33

Market Cap:

$3.83B

Revenue:

$1.29B

Net Income/Loss:

$251.00M

P/E Ratio:

16.44

EPS:

1.9744

Net Cash Flow:

$-193.86M

1W Performance:

-9.43%

1M Performance:

-5.53%

6M Performance:

+2.98%

1Y Performance:

+31.43%

1-Day Range:

$32.31

$33.84

1-Week Range:

$32.31

$36.32

52-Week Range:

$23.72

$42.81

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Name

Indivior Pharmaceuticals Inc

Sector

Healthcare (1052)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

804-379-1090

Address

10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD

Employee

838

Twitter

Next Earnings Date

2026-10-29

Latest SEC Filings

INDV's Discussions on Twitter

Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INDV Indivior Pharmaceuticals Inc	32.45	3.83B	1.29B	251.00M	-193.86M	1.9744
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-18-26	Initiated	Barclays	Overweight
Aug-06-25	Initiated	H.C. Wainwright	Buy
Jul-22-25	Resumed	Jefferies	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-23-24	Initiated	Piper Sandler	Overweight
Apr-03-24	Initiated	Craig Hallum	Buy
Jul-13-23	Initiated	Northland Capital	Outperform

View All

Indivior Pharmaceuticals Inc Stock (INDV) Latest News

Oct 15, 2026

With 77.27% of shares represented, Indivior (INDV) stockholders vote on merger-related share issuance. - Stock Titan

Oct 15, 2026

Oct 06, 2026

A $1B special dividend features in Indivior (INDV)'s revised merger valuation details. - Stock Titan

Oct 06, 2026

Indivior stock pre-market at EUR 32.10: plus 0.00 percent - AD HOC NEWS

Oct 06, 2026

Oct 02, 2026

Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.

Oct 02, 2026

Sep 30, 2026

Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

Sep 30, 2026

Three parties report a passive holding above 5% in Indivior (INDV). - Stock Titan

Sep 30, 2026

Sep 24, 2026

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire

Sep 24, 2026

Sep 17, 2026

Indivior (NASDAQ: INDV) Announces Conditional $8.13 Special Dividend Pending Merger Completion - Kalkine Media

Sep 17, 2026

Indivior Declares $8.13 Per Share Special Dividend Tied to Supernus Merger Closing - Minichart

Sep 17, 2026

An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan

Sep 17, 2026

Indivior declares $8.13 special dividend contingent on merger - Investing.com India

Sep 17, 2026

Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior

Sep 17, 2026

Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing - Quiver Quantitative

Sep 17, 2026

Indivior declares $8.13 special dividend contingent on merger - Investing.com

Sep 17, 2026

Sep 11, 2026

$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan

Sep 11, 2026

Sep 10, 2026

Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de

Sep 10, 2026

Sep 09, 2026

Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan

Sep 09, 2026

SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion - TradingView

Sep 09, 2026

Sep 04, 2026

Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de

Sep 04, 2026

Sep 03, 2026

Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance - AD HOC NEWS

Sep 03, 2026

Indivior stock gains on raised 2026 outlook and strong Sublocade growth - AD HOC NEWS

Sep 03, 2026

Sep 02, 2026